TABLE 1.
Sample name | Nb (86) | Collection date | Time point | ART therapy | VL (RNA copies/mL) | CD4 count (cells/mm3) | Sampled tissue |
---|---|---|---|---|---|---|---|
101600P | 21 | 16-Oct-00 | T1 | — | 456,987 | 277 | Plasma |
112000P | 20 | 20-Nov-00 | T2 | — | 801,458 | 619 | Plasma |
112800P | 5 | 28-Nov-00 | T3 | — | 367,984 | 551 | Plasma |
112800C | 5 | 28-Nov-00 | T3 | — | — | — | Plasma |
121800P | 4 | 18-Dec-00 | T4 | Zidovudine and lamivudine/nelfinavir | 3,966 | 585 | Plasma |
121800C | 3 | 18-Dec-00 | T4 | Zidovudine and lamivudine/nelfinavir | — | — | Plasma |
022201M | 3 | 22-Feb-01 | T5 | Zidovudine and lamivudine/nelfinavir | 7,011 | 638 | PBMC |
070201P | 4 | 02-Jul-01 | T6 | Zidovudine and lamivudine/efavirenz | 746 | 379 | Plasma |
070201C | 4 | 02-Jul-01 | T6 | Zidovudine and lamivudine/efavirenz | — | — | Plasma |
100901P | 3 | 09-Oct-01 | T7 | Zidovudine and lamivudine/efavirenz | <400 | 633 | Plasma |
100901M | 3 | 09-Oct-01 | T7 | Zidovudine and lamivudine/efavirenz | — | — | PBMC |
021202P | 3 | 12-Feb-02 | T8 | Zidovudine and lamivudine/efavirenz | <400 | 743 | Plasma |
021202M | 3 | 12-Feb-02 | T8 | Zidovudine and lamivudine/efavirenz | — | — | PBMC |
060302P | 3 | 03-Jun-02 | T9 | Zidovudine and lamivudine/efavirenz | <775 | 615 | Plasma |
060302C | 2 | 03-Jun-02 | T9 | Zidovudine and lamivudine/efavirenz | — | — | Plasma |
Samples are designated by blood collection date and a letter indicating whether the sequence was derived from PPT plasma (P), CPT plasma (C), or PBMC (M), followed by a clone number. For example, 101600P1 is a sequence from October 16, 2000 isolated from PPT plasma and is clone number 1. Infection date for this trial participant was estimated as September 21, 2000. PPT and CPT are different plasma preparation tubes. PBMC, peripheral blood mononuclear cells.
N, the number of sequences for each time point; the number in parentheses indicates the total number of sequences.